Lipid-lowering drugs
- 29 March 2006
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 63 (10) , 1165-1178
- https://doi.org/10.1007/s00018-005-5406-7
Abstract
Although a change in life-style is often the method of first choice for lipid lowering, lipid-lowering drugs, in general, help to control elevated levels of different forms of lipids in patients with hyperlipidemia. While one group of drugs, statins, lowers cholesterol, the other group, fibrates, is known to take care of fatty acids and triglycerides. In addition, other drugs, such as ezetimibe, colesevelam, torcetrapib, avasimibe, implitapide, and niacin are also being considered to manage hyperlipidemia. As lipids are very critical for cardiovascular diseases, these drugs reduce fatal and nonfatal cardiovascular abnormalities in the general population. However, a number of recent studies indicate that apart from their lipidlowering activities, statins and fibrates exhibit multiple functions to modulate intracellular signaling pathways, inhibit inflammation, suppress the production of reactive oxygen species, and modulate T cell activity. Therefore, nowadays, these drugs are being considered as possible therapeutics for several forms of human disorders including cancer, autoimmunity, inflammation, and neurodegeneration. Here I discuss these applications in the light of newly discovered modes of action of these drugs.Keywords
This publication has 98 references indexed in Scilit:
- Long-term statin use and psychological well-beingJournal of the American College of Cardiology, 2003
- Gemfibrozil, a Lipid-lowering Drug, Inhibits the Induction of Nitric-oxide Synthase in Human AstrocytesJournal of Biological Chemistry, 2002
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- Pitavastatin Enhanced BMP-2 and Osteocalcin Expression by Inhibition of Rho-Associated Kinase in Human OsteoblastsBiochemical and Biophysical Research Communications, 2001
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Cooperative Formation of Higher Order Peroxisome Proliferator-activated Receptor and Retinoid X Receptor Complexes on the Peroxisome Proliferator Responsive Element of the Rat Hydratase-Dehydrogenase GenePublished by Elsevier ,1995
- The role of peroxisomes in mammalian cellular metabolismJournal of Inherited Metabolic Disease, 1987
- Replication of arterial smooth muscle cells in hypertension and atherosclerosisThe American Journal of Cardiology, 1987
- Structure, composition, physical properties, and turnover of proliferated peroxisomes. A study of the trophic effects of Su-13437 on rat liver.The Journal of cell biology, 1975